ATE309346T1 - Antitumor-antisense sequenzen gegen die r1 und r2 komponenten der ribonukleotidreduktase - Google Patents
Antitumor-antisense sequenzen gegen die r1 und r2 komponenten der ribonukleotidreduktaseInfo
- Publication number
- ATE309346T1 ATE309346T1 AT00903456T AT00903456T ATE309346T1 AT E309346 T1 ATE309346 T1 AT E309346T1 AT 00903456 T AT00903456 T AT 00903456T AT 00903456 T AT00903456 T AT 00903456T AT E309346 T1 ATE309346 T1 AT E309346T1
- Authority
- AT
- Austria
- Prior art keywords
- components
- antisense sequences
- ribonucleotide reductase
- sequences against
- antitumor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/249,730 US6121000A (en) | 1999-02-11 | 1999-02-11 | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase |
PCT/CA2000/000120 WO2000047733A1 (en) | 1999-02-11 | 2000-02-09 | Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE309346T1 true ATE309346T1 (de) | 2005-11-15 |
Family
ID=22944744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00903456T ATE309346T1 (de) | 1999-02-11 | 2000-02-09 | Antitumor-antisense sequenzen gegen die r1 und r2 komponenten der ribonukleotidreduktase |
Country Status (17)
Country | Link |
---|---|
US (1) | US6121000A (de) |
EP (1) | EP1153128B8 (de) |
JP (1) | JP4424857B2 (de) |
KR (1) | KR20020013501A (de) |
CN (1) | CN1345373A (de) |
AR (1) | AR022583A1 (de) |
AT (1) | ATE309346T1 (de) |
AU (1) | AU780455B2 (de) |
BR (1) | BR0008788A (de) |
CA (1) | CA2366487A1 (de) |
DE (1) | DE60023845T2 (de) |
ES (1) | ES2259602T3 (de) |
IL (1) | IL144727A0 (de) |
MX (1) | MXPA01008137A (de) |
NZ (1) | NZ514090A (de) |
RU (1) | RU2001124840A (de) |
WO (1) | WO2000047733A1 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6593305B1 (en) * | 1996-08-02 | 2003-07-15 | Genesense Technologies Inc. | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase |
MXPA04010282A (es) * | 2002-04-18 | 2005-08-18 | Acuity Pharmaceuticals Inc | Medios y metodos para la inhibicion especifica de genes en celulas y tejido de cns y/u ojo. |
US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
JP2006518344A (ja) * | 2003-02-10 | 2006-08-10 | ジェネセンス テクノロジーズ インク | リボヌクレオチド還元酵素r2を指向するアンチセンスオリゴヌクレオチドおよび癌の治療におけるこれらの使用 |
EP1615943A4 (de) * | 2003-04-18 | 2006-08-16 | Univ Pennsylvania | Zusammensetzung und verfahren for sirna-inhibierung von angiopoietin 1 und 2 und deren rezeptor tie2 |
CN1302936C (zh) * | 2003-05-02 | 2007-03-07 | 精工爱普生株式会社 | 打印机 |
EP1636363A1 (de) * | 2003-05-21 | 2006-03-22 | GeneSense Technologies Inc. | Antisense oligonukleotide gegen die ribonukleotid reduktase r1 und deren verwendung für die behandlung von krebs |
WO2004106518A1 (en) * | 2003-05-31 | 2004-12-09 | Genesense Technologies Inc. | Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
WO2005065719A1 (en) * | 2004-01-12 | 2005-07-21 | Genesense Technologies Inc. | Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer |
CA2564868C (en) * | 2004-04-28 | 2013-11-26 | Molecules For Health, Inc. | Methods for treating or preventing restenosis and other vascular proliferative disorders |
WO2006017932A1 (en) * | 2004-08-18 | 2006-02-23 | Genesense Technologies Inc. | Small interfering rna molecules against ribonucleotide reductase and uses thereof |
US20090130212A1 (en) * | 2006-05-15 | 2009-05-21 | Physical Pharmaceutica, Llc | Composition and improved method for preparation of small particles |
WO2007146953A2 (en) * | 2006-06-12 | 2007-12-21 | Exegenics, Inc., D/B/A Opko Health, Inc. | Compositions and methods for sirna inhibition of angiogenesis |
US7872118B2 (en) * | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
US20080305157A1 (en) * | 2007-06-08 | 2008-12-11 | University Of Maryland Office Of Technology Commercialization | Encapsulation and separation of charged organic solutes inside catanionic vesicles |
EP2030615A3 (de) * | 2007-08-13 | 2009-12-02 | ELFORD, Howard L. | Ribonukleotidreduktase-Inhibitoren zur Verwendung für die Behandlung oder Vorbeugung von Nervenentzündung- oder Autoimmunerkrankungen |
US20100204305A1 (en) * | 2007-12-11 | 2010-08-12 | Lorus Therapeutics Inc. | Small interfering rna molecules against ribonucleotide reductase and uses thereof |
CA2745832A1 (en) | 2008-12-04 | 2010-06-10 | Opko Ophthalmics, Llc | Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms |
DE102019000490A1 (de) * | 2019-01-23 | 2020-07-23 | HAEMES Verwaltungsgesellschaft mbH | Verwendung von Oligonukleotiden für die Behandlung von Tumoren |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5225347A (en) * | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
US5719262A (en) * | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5766855A (en) * | 1991-05-24 | 1998-06-16 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity and sequence specificity |
US5681747A (en) * | 1992-03-16 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof |
EP0690869A1 (de) * | 1993-03-23 | 1996-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | Zelluläre regulation mittelsriboregulatoren |
WO1998005769A2 (en) * | 1996-08-02 | 1998-02-12 | Genesense Technologies, Inc. | Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase |
-
1999
- 1999-02-11 US US09/249,730 patent/US6121000A/en not_active Expired - Fee Related
-
2000
- 2000-02-09 WO PCT/CA2000/000120 patent/WO2000047733A1/en active IP Right Grant
- 2000-02-09 ES ES00903456T patent/ES2259602T3/es not_active Expired - Lifetime
- 2000-02-09 MX MXPA01008137A patent/MXPA01008137A/es not_active Application Discontinuation
- 2000-02-09 NZ NZ514090A patent/NZ514090A/en not_active IP Right Cessation
- 2000-02-09 RU RU2001124840/15A patent/RU2001124840A/ru unknown
- 2000-02-09 KR KR1020017010204A patent/KR20020013501A/ko not_active Application Discontinuation
- 2000-02-09 EP EP00903456A patent/EP1153128B8/de not_active Expired - Lifetime
- 2000-02-09 JP JP2000598631A patent/JP4424857B2/ja not_active Expired - Fee Related
- 2000-02-09 IL IL14472700A patent/IL144727A0/xx unknown
- 2000-02-09 CN CN00805667A patent/CN1345373A/zh active Pending
- 2000-02-09 AU AU25292/00A patent/AU780455B2/en not_active Ceased
- 2000-02-09 BR BR0008788-2A patent/BR0008788A/pt not_active Application Discontinuation
- 2000-02-09 CA CA002366487A patent/CA2366487A1/en not_active Abandoned
- 2000-02-09 AT AT00903456T patent/ATE309346T1/de not_active IP Right Cessation
- 2000-02-09 DE DE60023845T patent/DE60023845T2/de not_active Expired - Lifetime
- 2000-02-11 AR ARP000100613A patent/AR022583A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2000047733A1 (en) | 2000-08-17 |
EP1153128B1 (de) | 2005-11-09 |
RU2001124840A (ru) | 2004-03-27 |
DE60023845D1 (de) | 2005-12-15 |
EP1153128A1 (de) | 2001-11-14 |
KR20020013501A (ko) | 2002-02-20 |
AR022583A1 (es) | 2002-09-04 |
AU780455B2 (en) | 2005-03-24 |
DE60023845T2 (de) | 2006-08-10 |
JP4424857B2 (ja) | 2010-03-03 |
CA2366487A1 (en) | 2000-08-17 |
BR0008788A (pt) | 2001-11-06 |
AU2529200A (en) | 2000-08-29 |
EP1153128B8 (de) | 2006-01-18 |
WO2000047733A9 (en) | 2001-03-15 |
JP2003500006A (ja) | 2003-01-07 |
ES2259602T3 (es) | 2006-10-16 |
US6121000A (en) | 2000-09-19 |
CN1345373A (zh) | 2002-04-17 |
NZ514090A (en) | 2005-01-28 |
IL144727A0 (en) | 2002-06-30 |
MXPA01008137A (es) | 2004-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60023845D1 (de) | Antitumor-antisense sequenzen gegen die r1 und r2 komponenten der ribonukleotidreduktase | |
ATE450663T1 (de) | Verschleissteil und -anordnung | |
PL370163A1 (en) | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | |
SI1711470T1 (sl) | Derivati malonamida, ki blokirajo aktivnost gama-sekretaze | |
HK1054768B (zh) | 阻尼中間柱和使用它的阻尼結構 | |
HUP0600298A3 (en) | Reductive cleavage of the exocyclic ester of uk-2a or its derivatives and products formed therefrom | |
EP1453837A4 (de) | Zielgerichtete therapeutika und deren anwendungen | |
BRPI0208558A2 (pt) | preparado de combinação de estrogênio-gestagênio e uso | |
IL162653A0 (en) | Tyrosyl derivatives and their use as p2x7 receptormodulators | |
DE69903242D1 (de) | Sinterkörper hoher Festigkeit | |
ID30023A (id) | Kombinasi senyawa aktif fungisida | |
AU2003297612A8 (en) | 2-substituted-3-propenamide derivatives and methods of using the same | |
SI1372652T1 (sl) | Kombinacija docetaksela in flavopiridola | |
ID26881A (id) | Bubutan finer | |
SI1392670T1 (sl) | Substituirani C-furan-2-il-metilaminski in C-tiofen-2-il-metilaminski derivati | |
HUP0300198A3 (en) | Condensation derivatives of thiocolchicine and baccatin as antitumor agents | |
DE50010258D1 (de) | Metallisches Bauteil und Entladungslampe | |
IL162014A0 (en) | Shape-recovering material suitable for application of an attachment, and its use | |
NO990313A (no) | Klokke for personer med kognitive problemer | |
DE29901506U1 (de) | Metallbauelement | |
ATA17852001A (de) | Signaturarmer und schadstoffreduzierter, pyrotechnischer darstellungskörper | |
DE50115118D1 (de) | Mikromechanisches bauelement und abgleichverfahren | |
EP1392460A4 (de) | Fluorwasserstoffe von aminosilanolen und ihre verwendung | |
DE60140770D1 (de) | Fixier- und zwischenübertragungsrollen | |
ES1048676Y (es) | Base y cuerpo de andamio de estructura semiporticada. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |